Study Purpose:
This study evaluate use of a translated Norwegian version of the Edinburgh cognitive and behavioral amyotrophic lateral sclerosis screen (ECAS-N) as an early predictor in car-driving, working and use of advanced life-prolonging therapy.Study Status:
Recruiting
Disease:
Amyotrophic Lateral Sclerosis , Cognitive Impairment
Study Type:
Observational
Type of Intervention:
N/A
Intervention Name:
N/A
Placebo:
N/A
Phase:
N/A
Study Chair(s)/Principal Investigator(s):
Tina Taule, PhD, Haukeland University Hospital
Clinicaltrials.gov ID:
Neals Affiliated?
No
Coordinating Center Contact Information
Tina Taule, PhD / email hidden; JavaScript is required / +47 41694143
Full Study Summary:
Cognitive impairment is present in about 30-50% of the patients with amyotrophic lateral sclerosis (ALS). Screening of cognitive and behavioral impairment is a distinct recommendation in ALS-specific health care. However, knowledge in how cognitive impairment shall influence health-care professionals' information given to patients and in decision making is lacking.
One of the major challenges in ALS management is the decision-making on advanced therapy. There is a lack of knowledge in how cognitive impairment in ALS shall be interfere on complex medical treatment that will affect quality of life or life itself. This means significant implications not only to the ALS patient and the community, but also the family and especially the spouse. Thus, further investigation of the ECAS-N and its potential in clinical use is needed. The scale may contribute a more proactive treatment better tailored to individual needs. The objective is to evaluate if the ECAS-N can be applied as an early predictor in car-driving, working and use of advanced life-prolonging therapy
One of the major challenges in ALS management is the decision-making on advanced therapy. There is a lack of knowledge in how cognitive impairment in ALS shall be interfere on complex medical treatment that will affect quality of life or life itself. This means significant implications not only to the ALS patient and the community, but also the family and especially the spouse. Thus, further investigation of the ECAS-N and its potential in clinical use is needed. The scale may contribute a more proactive treatment better tailored to individual needs. The objective is to evaluate if the ECAS-N can be applied as an early predictor in car-driving, working and use of advanced life-prolonging therapy
Study Sponsor:
Haukeland University Hospital
Estimated Enrollment:
50
Estimated Study Start Date:
05 / 01 / 2017
Estimated Study Completion Date:
12 / 31 / 2022
Posting Last Modified Date:
08 / 09 / 2022
Date Study Added to neals.org:
07 / 06 / 2018
Minimum Age:
N/A
Maximum Age:
N/A
Inclusion Criteria:- Voluntary informed consent
- Native Norwegian speaker
Exclusion Criteria:
- Great difficulties in writing or reading
- Comorbid medical history
- Neurological disorders others than ALS
- Psychiatric history of importance to cognitive function
Haukeland University Hospital | Recruiting
Tina Taule, PhD / +47 41694143 / email hidden; JavaScript is required
Ole-Bjørn Tysnes, Professor / email hidden; JavaScript is required
Bergen 5021
Norway